search icon

    Market Snapshot

    • S&P Futures

      3,914.75

    • Dow Futures

      31,478

    • Nasdaq Futures

      12,132.75

    blog search icon

    Bicycle Therapeutics plc

    (NASDAQ:BCYC)

    $15.94

    $1.14

    7.70%

    Bicycle Therapeutics plc Chart

    BCYC Stock Price Today

    Bicycle Therapeutics plc (BCYC) stock rallied over 7.70% intraday to trade at $15.94 a share on NASDAQ. The stock opened with a gain of 11.94% at $14.75 and touched an intraday high of $16.04, rising 7.70% against the last close of $14.8. The stock went to a low of $14.75 during the session.

    Stock Snapshot

    $14.8

    Prev. Close

    417.95 Million

    Market Cap

    $14.75

    Day Low

    $14.75

    Open

    29.61 Million

    Number of Shares

    $16.04

    Day High

    -

    P/E ratio

    -2.88

    EPS (TTM)

    14.82

    Cash Flow per Share

    11.85

    Free Float in %

    6.67

    Book Value

    408,722

    Volume

    Bicycle Therapeutics plc Historical Data

    DateOpenHighLowCloseVolume
    2022-06-23$14.75$16.04$14.75$15.94408,800
    2022-06-22$14.24$15.425$14.24$14.8100,500
    2022-06-21$14.91$15.78$14.51$14.55197,800
    2022-06-17$12.98$15.3$12.98$14.64568,700
    2022-06-16$13.16$13.22$12.08$12.95387,000
    2022-06-15$13.28$13.569$12.92$13.491,196,200
    2022-06-14$13.5$13.64$12.76$13.05812,300
    2022-06-13$13.27$13.75$12.455$13.5587,500
    2022-06-10$14.26$14.3$13.52$13.6254,400
    2022-06-09$14.83$14.92$14.3$14.64233,000

    Contact Details

    Babraham Research Campus
    Building 900
    Cambridge CB22 3AT
    United Kingdom

    Webiste:BCYC

    44 1223 261 503

    Company Information

    Employees-

    Beta-

    Sales or Revenue11.7 Million

    5Y Sales Change-

    Fiscal Year Ends2021-12-30

    SectorHealth Care

    IndustryBiotechnology

    About Company

    Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics. Its lead product candidate is BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease. The company's oncology product candidates also comprise BT5528, a BTC that is in a Phase I/II clinical trial targeting EphA2; and BT8009, which is in Phase I/II clinical trial targeting Nectin-4. In addition, it is developing THR-149, a plasma kallikrein inhibitor that completed Phase II clinical trials for the treatment of diabetic macular edema; BT7480, a Bicycle tumor-targeted immune cell agonist (TICA) targeting Nectin-4 and agonizing; BT7455, an EphA2/CD137 Bicycle TICA, which is in preclinical studies; and BT1718, a BTC that target tumors, that is in Phase I/IIa clinical trial that express Membrane Type 1 matrix metalloproteinase. Further, the company collaborates with biopharmaceutical companies and organizations to develop programs in therapeutic areas, such as anti-infective, cardiovascular, ophthalmology, and respiratory indications. It has a clinical trial and license agreement with the Cancer Research Technology Limited and Cancer Research UK; research collaboration agreements with AstraZeneca, Sanofi, Oxurion, and the Dementia Discovery Fund; and discovery collaboration and license agreement with Genentech for the discovery and development of Bicycle peptides for multiple immuno-oncology targets. Bicycle Therapeutics plc was incorporated in 2009 and is headquartered in Cambridge, the United Kingdom.

    Frequently Asked Questions

    icon

    What is the current Bicycle Therapeutics plc (BCYC) stock price?

    Bicycle Therapeutics plc (NASDAQ: BCYC) stock price is $15.94 as of the last check on Thursday, June 23. During the trading session, BCYC stock reached the peak price of $16.04 while $14.75 was the lowest point it dropped to.

    icon

    BCYC's industry and sector of operation?

    The NASDAQ listed BCYC is part of Biotechnology industry that operates in the broader Health Care sector. Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics. Its lead product candidate is BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease.

    icon

    Who are the executives of BCYC?

    Dr. Kevin Lee M.B.A., Ph.D.
    CEO & Exec. Director
    Mr. Lee H. Kalowski M.B.A., MBA
    Pres & CFO
    Sir Gregory Paul Winter CBE, FMedsci, FRS, HonFRCP, HonFTSE
    Co-Founder, Non-Exec. Director & Member of Scientific Advisory Board
    Dr. Michael Skynner B.sc. Ph.d., Ph.D.
    Chief Technology Officer

    icon

    What is the BCYC stock price today?

    BCYC stock traded closed the last session at $15.94, which is $1.14 or 7.70% lower than its previous close of $14.8. BCYC's current trading price is 31.95% lower than its 52-week high of $62.08 where as its distance from 52-week low of 12.08% is -74.32%.

    icon

    How many employees does BCYC have?

    Number of BCYC employees currently stands at -. BCYC operates from Babraham Research Campus, Building 900, Cambridge CB22 3AT, United Kingdom.

    icon

    Link for BCYC official website?

    Official Webiste of $BCYC is: https://www.bicycletherapeutics.com

    icon

    How do I contact BCYC?

    BCYC could be contacted at BCYC operates from Babraham Research Campus, Building 900, Cambridge CB22 3AT, United Kingdom, or at phone #44 1223 261 503 and can also be accessed through its website.

    icon

    How many shares of BCYC are traded daily?

    BCYC stock volume for the day was 408,722 shares while in the previous session number of BCYC shares traded was 408,800 . The average number of BCYC shares traded daily for last 3 months was 636.76 Thousands.

    icon

    How much did BCYC change today?

    The percentage change in BCYC stock occurred in the recent session was 7.70% while the dollar amount for the price change in BCYC stock was $1.14.

    icon

    What price range BCYC stock been trading in?

    In the recent session, the day high for BCYC stock was $16.04 while the low for BCYC stock touched on the day was $14.75.

    icon

    What is the market cap of BCYC currently?

    The market value of BCYC currently stands at 417.95 Million with its latest stock price at $15.94 and 29.61 Million of its shares outstanding.